文献速递临床试验与 GCP

头颈癌大手术中静脉利多卡因的评估:一项随机对照试验的研究方案

Evaluation of intravenous lidocaine in head and neck cancer surgery: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2019-04-15

本研究为前瞻性两中心双盲随机对照试验,计划纳入128例头颈癌大手术患者,随机接受静脉利多卡因或安慰剂。主要结局为术后48小时吗啡消耗量,次要结局包括术中瑞芬太尼消耗量、术后24小时吗啡消耗量及术后3-6个月慢性术后疼痛。

要点

  • 头颈癌大手术患者无法从区域麻醉主导的多模式镇痛中充分获益。
  • 静脉利多卡因在部分手术中可减少急性疼痛和阿片类药物用量,并可能预防慢性术后疼痛。
  • 这是首个在头颈癌大手术中前瞻性评估静脉利多卡因疗效与安全性的试验。

核心结论

  • 作者假设围术期静脉输注利多卡因可减少阿片类药物用量并降低慢性术后疼痛。
  • 近期证据提示静脉利多卡因可在某些类型手术中减少阿片类药物用量并降低慢性术后疼痛。
  • 这是首个在头颈癌大手术中前瞻性评估静脉利多卡因疗效与安全性的试验。

研究设计与样本

  • 前瞻性两中心双盲随机对照试验,计划纳入128例接受头颈癌大手术的患者。
  • 患者随机分配至利多卡因组或安慰剂组。
  • 全身麻醉诱导后给予静脉利多卡因负荷量1.5 mg.kg-1,随后持续输注2 mg.kg-1.h-1,在麻醉后监护室减至1 mg.kg-1.h-1。
  • 主要结局为术后48小时吗啡消耗量。
  • 次要结局包括术中瑞芬太尼消耗量、术后24小时吗啡消耗量及术后3-6个月评估的慢性术后疼痛。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pain after major head and neck cancer surgery is underestimated and has both nociceptive and neuropathic characteristics. Extended resection, flap coverage, nerve lesions, inflammation, and high-dose opioid administration can also lead to hyperalgesia and chronic postoperative pain. Opioids are frequently associated with adverse events such as dizziness, drowsiness, nausea and vomiting, or constipation disturbing postoperative recovery and extending the length of hospital stay. Patients eligible for major head and neck cancer surgery cannot benefit from full multimodal pain management with locoregional anesthesia. Intravenous lidocaine, investigated in several studies, has been found to decrease acute pain and morphine consumption. Some data suggest also that it can prevent chronic postsurgical pain. Evidence supporting its use varies between surgical procedures, and there is no published study regarding systemic lidocaine administration in major head and neck cancer surgery. We hypothesized that intravenous lidocaine infused in the perioperative period would lead to opioid sparing and chronic postsurgical pain reduction. METHODS/DESIGN: A total of 128 patients undergoing major head and neck surgery will be included in this prospective two-center, double-blind, randomized controlled trial. Patients will be randomly assigned to lidocaine or placebo treatment. After induction of general anesthesia, an intravenous lidocaine bolus will be administered (1.5 mg.kg- 1), followed by a continuous infusion (2 mg.kg- 1.h- 1) which will be reduced in the postanesthesia care unit (1 mg.kg- 1.h- 1). The primary outcome measure is morphine consumption 48 h after surgery. The secondary outcomes include intraoperative remifentanil consumption, morphine consumption 24 h after surgery, and chronic postsurgical pain that will be assessed 3-6 months after surgery. DISCUSSION: Recent evidence suggests that intravenous lidocaine can lead to opioid sparing and chronic postsurgical pain reduction for certain types of surgery. This is the first trial to prospectively investigate the efficacy and safety of intravenous lidocaine in major head and neck cancer surgery. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02894710 . Registered on 11 August 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Omar E, Wallon G, Bauer C, et al. Evaluation of intravenous lidocaine in head and neck cancer surgery: study protocol for a randomized controlled trial. Trials. 2019. PMID: 30987664. doi:10.1186/s13063-019-3303-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。